All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

Breaking the big Five Barriers of Brain Metastasis: A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain CA209-7WF / Break B5-BM-NSCLC

This clinical trial is studying a new treatment approach for people with advanced non-small-cell lung cancer that has spread to the brain (known as brain metastases). Treating tumours in the brain can be very difficult because the brain naturally blocks many standard medicines. In this study, researchers are combining five different medications. These include two immunotherapy drugs (nivolumab and ipilimumab) that help your immune system recognise and attack cancer cells, a targeted drug (bevacizumab) that cuts off the blood supply to tumours, and two cycles of standard chemotherapy (carboplatin and paclitaxel). The main aim of the trial is to see if this five-drug combination is safe, manageable, and effective at shrinking brain tumours or keeping them stable for at least six months. Doctors will also track how long patients live and how the treatment affects their daily quality of life.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Universitaetsklinikum Regensburg AöR
Enrolment target
39
Start
26 Aug 2024

What is this study about?

Lung cancer is one of the most common cancers in the UK. In some cases, cancer cells can travel from the lungs into the brain. These are known as brain metastases. Treating brain tumours is particularly challenging because the body has a natural barrier that protects the brain, which often stops standard cancer drugs from getting through.

This trial, called 'Break B5', is testing a powerful combination of treatments designed to tackle these barriers. Instead of using just one or two drugs, doctors are testing five medicines working together. The plan combines two immunotherapy medicines (which help the body's natural defences attack cancer), one targeted medicine (which stops tumours from growing new blood vessels), and two standard chemotherapy medicines to directly kill fast-growing cells.

The main purpose of this study is to find out if this combination is safe and how well it controls cancer in the brain. The research team will track whether tumours shrink or stop growing for at least six months. They will also look at overall survival, how long the treatment keeps the cancer controlled elsewhere in the body, and how patients feel during treatment using regular quality-of-life surveys.

Key takeaways

  • Tests a five-drug combination including immunotherapy, targeted therapy, and chemotherapy.
  • Aimed at adults with non-squamous non-small-cell lung cancer that has spread to the brain.
  • Mainly focuses on safety and whether the treatment shrinks or controls brain tumours.
  • All participants receive the active study medications (no placebo is used).
  • Participation is entirely voluntary, and you can stop at any time.

Who may be eligible?

This trial is open to men and women aged 18 and over who have a specific type of lung cancer called non-squamous non-small-cell lung cancer that has spread to the brain.

To be considered, you will need to be well enough in your day-to-day life to cope with medical treatments, and your vital organs (such as your liver, kidneys, and heart) must be working reasonably well. Some patients who have previously had focused radiation treatment to the brain may still be able to join.

You might not be able to take part if you have certain active autoimmune conditions, serious infections, or other severe health problems that could make the treatment unsafe. The hospital research team will look closely at your medical history, scans, and blood test results to decide whether this trial is safe and suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with non-squamous non-small-cell lung cancer.
  3. My cancer has spread to my brain (brain metastases).
  4. I am well enough to attend regular hospital appointments and manage daily activities.
  5. I am open to receiving treatment via a drip into a vein.
Answer every question to see your result.

What does participation involve?

If you join the trial, you will receive all your study medicines through a drip into a vein (an intravenous infusion) at a hospital clinic. Treatment begins with an initial phase that includes chemotherapy, targeted therapy, and immunotherapy, followed by ongoing maintenance therapy. You will visit the clinic regularly for treatment and check-ups. During these visits, doctors will carry out brain MRI scans, body CT scans, physical examinations, and routine blood tests to see how the cancer is responding. You will also be asked to complete short questionnaires about your symptoms and daily functioning. Taking part may last from several months to over two years, depending on how well the cancer responds to the drugs and how you feel.

Potential risks and benefits

The main benefit of taking part is the possibility that this combination could shrink or control your tumours, including those in the brain, although there is no guarantee it will work for everyone. Your participation also helps researchers develop better treatments for people with lung cancer in the future. However, combining multiple strong medicines can cause side effects. These may include severe tiredness, sickness, skin rashes, high blood pressure, or inflammation in organs such as the bowels, liver, or lungs caused by the immune system. Doctors will monitor your health very closely and can adjust doses or offer supportive medicines if problems arise. Joining is entirely your choice, and you are free to leave the trial at any time without your usual NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany

Common questions

What is immunotherapy?

Immunotherapy is a type of cancer treatment that boosts your body's own immune system, helping it recognise and destroy cancer cells.

Will I definitely receive the trial medicines?

Yes. This is an open-label study, which means there is no dummy drug (placebo). Every person who takes part receives the active combination of study medicines.

Do I have to pay to take part?

No. The trial medicines and any extra tests required for the study are provided free of charge, usually through the NHS.

Can I leave the study if I change my mind?

Yes, absolutely. Taking part is completely voluntary. You can withdraw from the trial at any point, and your normal NHS care and doctor's support will continue unchanged.

How often will I need brain scans?

You will have regular MRI scans of your brain every few weeks or months so your doctors can closely track how the tumours are responding to treatment.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Breaking the big Five Barriers of Brain Metastasis: A prospe…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.